Publicacions - IR Sant Pau

Cercar

01/04/2026 Two exploratory studies to investigate the role of self and emotional dysregulation in borderline personality disorder

Soler, J, Borao, L, Schmidt, C, Martinez-Rubio, D, Cebolla, A, Montero-Marin, J, García-Campayo, J, Gascon-Santos, S, Pascual, JC. Two exploratory studies to investigate the role of self and emotional dysregulation in borderline personality disorder. EUROPEAN JOURNAL OF PSYCHIATRY. 2026; 40(2)DOI:10.1016/j.ejpsy.2026.100347. PMID:. IF:1.500(Q3/7D).

01/11/2025 Defining the Patient Journey and Identifying Digital Health Solutions in Treatment-Resistant Schizophrenia

Grasa, E, Forment, A, Alonso-Solís, A, Ramalho, L, Roldán, A, Pousa, E, Aussó, S, Berdun, J, Tesoro, AG, Escudero, J, Corripio, I. Defining the Patient Journey and Identifying Digital Health Solutions in Treatment-Resistant Schizophrenia. ACTAS ESPANOLAS DE PSIQUIATRIA. 2025; 53(6)DOI:10.62641/aep.v53i6.1959. PMID:41437755. IF:1.600(Q3/7D).

01/04/2026 Compulsive sexual behavior in cocaine use disorder: Treatment outcomes and clinical challenges

Palazón-Llecha, A, Trujols, J, Madre, M, Duran-Sindreu, S, Batlle, F, Mallorquí-Bagué, N. Compulsive sexual behavior in cocaine use disorder: Treatment outcomes and clinical challenges. ACTA PSYCHOLOGICA. 2026; 264DOI:10.1016/j.actpsy.2026.106574. PMID:41812393. IF:2.700(Q2/3D).

01/01/2026 Pharmacological management of an agitated patient in the emergency department

Ramos, JR, Rovira, MC, Sindreu, MDC, Marquez, PP, Carrillo, SZ, Rios, IP, Egea, ER, Blas, FS, Planella, MP, Piera, OM, Campmany, MP. Pharmacological management of an agitated patient in the emergency department. Pharmaceutical Care Espana. 2026; 28DOI:10.60103/phc.v27.e920. PMID:. IF:(Q/D).

01/10/2021 TMEM106B and CPOX are genetic determinants of cerebrospinal fluid Alzheimer's disease biomarker levels

Hong, SJ, Dobricic, V, Ohlei, O, Bos, I, Vos, SJB, Prokopenko, D, Tijms, BM, Andreasson, U, Blennow, K, Vandenberghe, R, Gabel, S, Scheltens, P, Teunissen, CE, Engelborghs, S, Frisoni, G, Blin, O, Richardson, JC, Bordet, R, Lleo, A, Alcolea, D, Popp, J, Clark, C, Peyratout, G, Martinez-Lage, P, Tainta, M, Dobson, RJB, Legido-Quigley, C, Sleegers, K, Van Broeckhoven, C, Tanzi, RE, ten Kate, M, Wittig, M, Franke, A, Lill, CM, Barkhof, F, Lovestone, S, Streffer, J, Zetterberg, H, Visser, PJ, Bertram, L, Neuroimaging Initiative. TMEM106B and CPOX are genetic determinants of cerebrospinal fluid Alzheimer's disease biomarker levels. ALZHEIMERS & DEMENTIA. 2021; 17(10)DOI:10.1002/alz.12330. PMID:33991015. IF:16.655(Q1/1D).

19/02/2024 Functional brain connectivity prior to the COVID-19 outbreak predicts mental health trajectories during two years of pandemic

Cabello-Toscano, M, Vaqué-Alcázar, L, Bayes-Marin, I, Cattaneo, G, Solana-Sánchez, J, Mulet-Pons, L, Bargalló, N, Tormos, JM, Pascual-Leone, A, Bartrés-Faz, D. Functional brain connectivity prior to the COVID-19 outbreak predicts mental health trajectories during two years of pandemic. PSYCHIATRY AND CLINICAL NEUROSCIENCES. 2024; 78(4)DOI:10.1111/pcn.13654. PMID:38372461. IF:6.200(Q1/1D).

23/08/2024 Benefits of Living Over Deceased Donor Kidney Transplantation in Elderly Recipients. A Propensity Score Matched Analysis of a Large European Registry Cohort

Toapanta, N, Comas, J, Revuelta, I, Manonelles, A, Facundo, C, Pérez-Saez, MJ, Vila, A, Arcos, E, Tort, J, Giral, M, Naesens, M, Kuypers, D, Asberg, A, Moreso, F, Bestard, O. Benefits of Living Over Deceased Donor Kidney Transplantation in Elderly Recipients. A Propensity Score Matched Analysis of a Large European Registry Cohort. TRANSPLANT INTERNATIONAL. 2024; 37DOI:10.3389/ti.2024.13452. PMID:39263600. IF:3.000(Q1/1D).

01/08/2024 Oral quinolones versus intravenous ß-lactam for the treatment of acute focal bacterial nephritis: a retrospective cohort study

Aceituno, L, Nuñez-Conde, A, Serra-Pladevall, J, Viñado, B, Castella, E, Escolà-Vergé, L, Pigrau, C, Falcó, V, Len, YO. Oral quinolones versus intravenous ß-lactam for the treatment of acute focal bacterial nephritis: a retrospective cohort study. EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES. 2024; 43(8)DOI:10.1007/s10096-024-04871-2. PMID:38856826. IF:3.000(Q2/4D).

19/08/2024 'Gout was like the boss'. A qualitative study exploring the impact of gout on employment

Diaz-Torne, C, Pou, MA, Horne, A, Gasteiger, C, Dalbeth, N. 'Gout was like the boss'. A qualitative study exploring the impact of gout on employment. RMD Open. 2024; 10(3)DOI:10.1136/rmdopen-2024-004443. PMID:39160089. IF:4.700(Q1/1D).

01/04/2024 Application of the 2023 ACR/EULAR classification criteria for calcium pyrophosphate deposition disease in a seronegative rheumatoid arthritis cohort

Codes-Méndez, H, Sainz, L, Park, HS, Corominas, H, Diaz-Torne, C. Application of the 2023 ACR/EULAR classification criteria for calcium pyrophosphate deposition disease in a seronegative rheumatoid arthritis cohort. RMD Open. 2024; 10(2)DOI:10.1136/rmdopen-2024-004173. PMID:38626930. IF:4.700(Q1/1D).

01/08/2024 Diagnosed and undiagnosed cough-related stress urinary incontinence in women with refractory or unexplained chronic cough: Its impact on general health status and quality of life

Arismendi, E, Puente-Maestu, L, Domingo, C, Dávila, I, Quirce, S, González-Barcala, FJ, Crespo-Lessmann, A, Sánchez-Jareño, M, Rivas-Pardinas, C, Cea-Calvo, L. Diagnosed and undiagnosed cough-related stress urinary incontinence in women with refractory or unexplained chronic cough: Its impact on general health status and quality of life. Chronic Respiratory Disease. 2024; 21DOI:10.1177/14799731241273751. PMID:39222070. IF:2.300(Q2/5D).

01/05/2026 Integrase versus protease inhibitor therapy in advanced HIV disease (LAPTOP): a multicountry, randomised, open-label, non-inferiority trial

Behrens, GMN, Assoumou, L, Liegeon, G, Antinori, A, Micán, R, Genderini, FG, Post, FA, Rockstroh, JK, Hamzah, L, Domingo, P, Curran, A, Laguno, M, Fletcher, C, Moody, J, Pozniak, A. Integrase versus protease inhibitor therapy in advanced HIV disease (LAPTOP): a multicountry, randomised, open-label, non-inferiority trial. LANCET INFECTIOUS DISEASES. 2026; 26(5)DOI:10.1016/S1473-3099(25)00681-4. PMID:41344354. IF:31.000(Q1/1D).

04/03/2026 Dolutegravir restores gut microbiota in late-stage HIV-1 unlike darunavir: an open-label, randomized clinical trial

Català-Moll, F, Blázquez-Bondia, C, Farré-Badia, J, Torres, F, Manzardo, C, Bonfill, E, Curran, A, Domingo, P, Podzamczer, D, Force, L, Falcó, V, Parera, M, Casadellà, M, Miró, JM, Noguera-Julian, M, Paredes, R. Dolutegravir restores gut microbiota in late-stage HIV-1 unlike darunavir: an open-label, randomized clinical trial. Nature Communications. 2026; 17(1)DOI:10.1038/s41467-026-69846-7. PMID:41781390. IF:15.700(Q1/1D).

28/03/2024 Multiomics plasma effects of switching from triple antiretroviral regimens to dolutegravir plus lamivudine

de Lazzari, E, Negredo, EB, Domingo, P, Tiraboschi, JM, Ribera, E, Abdulghani, N, Alba, V, Fernández-Arroyo, S, Viladés, C, Peraire, J, Gatell, JM, Blanco, JL, Vidal, F, Rull, A, Martinez, E. Multiomics plasma effects of switching from triple antiretroviral regimens to dolutegravir plus lamivudine. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY. 2024; 79(5)DOI:10.1093/jac/dkae083. PMID:38546974. IF:3.600(Q2/3D).

28/03/2024 Evolving AIDS- and non-AIDS Mortality and Predictors in the PISCIS Cohort of People Living With HIV in Catalonia and the Balearic Islands (Spain), 1998-2020

Nomah, DK, Jamarkattel, S, Bruguera, A, Moreno-Fornés, S, Díaz, Y, Alonso, L, Aceitón, J, Llibre, JM, Domingo, P, Saumoy, M, Homar, F, Fanjul, F, Navarro, J, de la Mora, L, Knobel, H, Orti, A, Martin-Iguacel, R, Miró, JM, Casabona, J, Reyes-Urueña, J. Evolving AIDS- and non-AIDS Mortality and Predictors in the PISCIS Cohort of People Living With HIV in Catalonia and the Balearic Islands (Spain), 1998-2020. Open Forum Infectious Diseases. 2024; 11(4)DOI:10.1093/ofid/ofae132. PMID:38560603. IF:3.800(Q1/3D).

01/01/2024 Medical oncology workload, workforce census, and needs in Spain: two nationwide studies by the Spanish Society of medical oncology

Fernandez Montes A., Elez E., de la Haba-Rodriguez J., Paez D., Mendez-Vidal M.J., Felip E., Rodriguez-Lescure A.. Medical oncology workload, workforce census, and needs in Spain: two nationwide studies by the Spanish Society of medical oncology. Clinical & Translational Oncology. 2024; 26DOI:10.1007/s12094-023-03225-2. PMID:37316754. IF:2.500(Q3/6D).

02/05/2026 Pleomorphic rhabdomyosarcoma, outcomes of patients with advanced disease treated with systemic agents: Retrospective study from the global pushing ultra-rare sarcomas towards hope (PUSH) consortium

Baldi, GG, Giani, C, Ljevar, S, Denu, RA, Napolitano, A, Han, I, Brunello, A, Bhadri, V, Sebio, A, Andelkovic, V, Campos, F, Scanferla, R, Abreu, MH, Desar, IME, Ogura, K, Wong, DD, Bae, S, Bakhshi, S, Lefler, DS, Marquina, G, Mazzocca, A, Nakazawa, MS, Thway, K, Kim, HS, Chiusole, B, Connolly, EA, Terés, R, Antonescu, C, Bellan, E, Bovee, JVMG, Davis, JL, Tos, APD, Di Blasi, E, Lazar, AJ, Sbaraglia, M, Schaefer, IM, Taverna, S, Gronchi, A, Miceli, R, Chen, TW, Stacchiotti, S. Pleomorphic rhabdomyosarcoma, outcomes of patients with advanced disease treated with systemic agents: Retrospective study from the global pushing ultra-rare sarcomas towards hope (PUSH) consortium. EUROPEAN JOURNAL OF CANCER. 2026; 238DOI:10.1016/j.ejca.2026.116666. PMID:41819027. IF:7.100(Q1/2D).

01/05/2026 Sotorasib in Advanced KRAS G12C-Mutated NSCLC Results From the Global Expanded Access Program Including Patients With Poor Performance Status and a History of CNS Metastases

Novello, S, Rabinovich, NM, Shih, JY, Pelizzari, G, Stevenson, J, Majem, M, Ferreira, CG, Petty, WJ, Arriola, E, Castagneris, N, De Castro, J, Morbeck, I, Bauman, J, Toschi, L, Zer, A, Metro, G, Kalmadi, S, Martinez, AA, Al Husaini, H, Meloni, AR, Nduka, C, Ardito-Abraham, C, Xia, CH, Awad, MM. Sotorasib in Advanced KRAS G12C-Mutated NSCLC Results From the Global Expanded Access Program Including Patients With Poor Performance Status and a History of CNS Metastases. Jto Clinical And Research Reports. 2026; 7(5)DOI:10.1016/j.jtocrr.2026.100974. PMID:42006282. IF:(Q/D).

01/05/2026 Response rate and long-term survival in patients with advanced melanoma: data from the prospective cohort study gem-1801

Espinosa, E, Berciano-Guerrero, MA, Muñoz-Couselo, E, Puértolas, T, Manzano, JL, Soria, A, De Miguel, PA, Crespo, G, Sanz, LG, Cerezuela-Fuentes, P, de la Rosa, CA, Majem, M, Castaño, AG, Berrocal, A, Arroyo, FRG, de la Borbolla, MR, Bellido, L, Martínez, JM, Fernández, LA, Carnicero, AM, Castro, RL, Rodríguez, AB, Lecumberri, MJ, Guzmán, JCV, Balea, BC, Rodríguez, JF, Bautista, JV, Pérez, VN, Mujika, K, Subias, MC, Hernández, B, Algarra, SM, Márquez-Rodas, I. Response rate and long-term survival in patients with advanced melanoma: data from the prospective cohort study gem-1801. Clinical & Translational Oncology. 2026; 28(5)DOI:10.1007/s12094-025-04098-3. PMID:41313559. IF:2.500(Q3/6D).

15/04/2026 Decoding B-cell Signatures of Complete Pathologic Response to Perioperative Chemoimmunotherapy in Non-Small Cell Lung Cancer

Sierra-Rodero, B, Gil-González, A, Molina-Alejandre, M, Nadal, E, Calvo, V, Lázaro, M, Insa, A, Massuti, B, Marti, AM, de Castro, J, Campelo, RG, Larriba, JLG, Bernabé, R, Dómine, M, Aix, SP, Cobo, M, Camps, C, Reguart, N, Bosch-Barrera, J, Majem, M, Aguilar, A, Palmero, R, Clemente, MB, Martín-López, J, Muñoz-Viana, R, Megías, D, Gutiérrez-Escobedo, JM, Martínez-Toledo, C, Cruz-Bermúdez, A, Provencio, M. Decoding B-cell Signatures of Complete Pathologic Response to Perioperative Chemoimmunotherapy in Non-Small Cell Lung Cancer. CLINICAL CANCER RESEARCH. 2026; 32(8)DOI:10.1158/1078-0432.CCR-25-3315. PMID:41805895. IF:10.200(Q1/1D).

01/05/2026 Final overall survival results from EORTC 1333/PEACE-3 trial of enzalutamide plus radium-223 in metastatic castration-resistant prostate cancer

Gillessen, S, Gallardo, E, Choudhury, A, Saad, F, Soares, A, Loriot, Y, McDermott, R, Rodriguez-Vida, A, Velho, PI, Nolè, F, Cruz, F, Roumeguere, T, Daugaard, G, Yamamura, R, Bompas, E, Maroto, P, Veiga, FG, Skoneczna, I, da Trindade, KM, Carcano, FM, Lecouvet, F, Coens, C, Poncet, C, Fournier, B, Tombal, B. Final overall survival results from EORTC 1333/PEACE-3 trial of enzalutamide plus radium-223 in metastatic castration-resistant prostate cancer. ANNALS OF ONCOLOGY. 2026; 37(5)DOI:10.1016/j.annonc.2026.02.009. PMID:41763609. IF:65.400(Q1/1D).

19/04/2026 Progression-Free Survival 2 as a Potential Surrogate for Overall Survival in Glioblastoma: Insights From a Spanish Multicentric Cohort

Yaringaño, J, Mirallas, O, Navarro, V, Gómez-Puerto, D, Velilla, G, Vaz, MA, Gorria, T, Martínez-Monino, A, Hernández, A, Aguado, M, Di Muzio, A, Valbuena, DL, Ruiz-Pace, F, González, M, Martínez-García, M, Villacampa, G, Balaña, C, Carles, J, Dienstmann, R, Pineda, E, Sepúlveda, JM, Vieito, M. Progression-Free Survival 2 as a Potential Surrogate for Overall Survival in Glioblastoma: Insights From a Spanish Multicentric Cohort. Cancer Medicine. 2026; 15(4)DOI:10.1002/cam4.71825. PMID:42002922. IF:3.100(Q2/5D).

28/04/2026 Immune classification of advanced melanoma identifies non-responders to anti-PD1 therapy

Gámez-Pozo, A, Trilla-Fuertes, L, Becerril-Gómez, F, Lalanda-Delgado, P, Soriano, V, Goldaraz, FG, Lecumberri, MJ, de la Borbolla, MR, Majem, M, Pérez-Ruiz, E, González-Cao, M, Oramas, J, López-Vacas, R, Magdaleno, A, Fra, J, Martín-Carnicero, A, Corral, M, Puértolas, T, Ramos-Ruiz, R, Espinosa, E, Vara, JAF. Immune classification of advanced melanoma identifies non-responders to anti-PD1 therapy. CANCER IMMUNOLOGY IMMUNOTHERAPY. 2026; 75(5)DOI:10.1007/s00262-026-04392-1. PMID:42047827. IF:5.100(Q1/3D).

01/03/2026 Impact of Cell-Free TNA Fraction on Analytical Success in Liquid Biopsy for Lung Adenocarcinoma: Experience from a Tertiary Hospital

Herrera, IC, Cols, LC, Pijuan-Andujar, L, Cajo, SA, Montalvan, RG, Calvente, MG, Luque, GA, Gallardo, A, Jaramillo, JFC. Impact of Cell-Free TNA Fraction on Analytical Success in Liquid Biopsy for Lung Adenocarcinoma: Experience from a Tertiary Hospital. LABORATORY INVESTIGATION. 2026; 106(3)DOI:10.1016/j.labinv.2025.105990. PMID:. IF:4.200(Q1/1D).

01/07/2026 Mullerian adenosarcoma of the uterus, ovary and peritoneum: Whole transcriptomic digital spatial profiling (DSP) in a cohort of 42 tumors

D'Angelo, E, Kingsley, LG, Espinosa, I, Cipriani, V, Marotta, A, Nasr, S, Zdravkovic, S, Howitt, BE, Prat, J. Mullerian adenosarcoma of the uterus, ovary and peritoneum: Whole transcriptomic digital spatial profiling (DSP) in a cohort of 42 tumors. HUMAN PATHOLOGY. 2026; 173DOI:10.1016/j.humpath.2026.106117. PMID:41932512. IF:2.600(Q2/4D).

01/03/2026 Serous Tubal Intraepithelial Carcinoma (STIC): Incidence and Clinical Implications in 254 Consecutive Cases from a Tertiary Care Hospital

Misad, C, Cajo, SA, Espadaler, I, Muñoz, R, D'Angelo, E, Gallardo, A, Espinosa, I, Prat, J. Serous Tubal Intraepithelial Carcinoma (STIC): Incidence and Clinical Implications in 254 Consecutive Cases from a Tertiary Care Hospital. LABORATORY INVESTIGATION. 2026; 106(3)DOI:10.1016/j.labinv.2025.105314. PMID:. IF:4.200(Q1/1D).

01/02/2026 Cardiac plasmacytoma with extensive infiltration: multimodal diagnosis and therapeutic challenges: a case report

Rodríguez-Fraga, P, Cascos, E, Cuartas, A, Espadaler, I. Cardiac plasmacytoma with extensive infiltration: multimodal diagnosis and therapeutic challenges: a case report. European Heart Journal-Case Reports. 2026; 10(2)DOI:10.1093/ehjcr/ytag102. PMID:41728229. IF:(Q/D).

01/03/2026 ctDNA clearance after induction therapy as predictor of response to radical chemoradiotherapy in locally advanced head and neck cancer

Bruixola, G, Martín-Arana, J, Vidales, Z, Peon, G, Gimeno-Valiente, F, Tous, S, Camblor, DG, Cirauqui, B, García-Bartolomé, M, Sumarroca, A, Martínez-Castedo, B, Leon, X, Micó-García, B, Iglesias-Martínez, B, García-March, A, Segui, V, Pavón, MA, Quirós, B, Clavero, O, Maroñas, M, Escorihuela-Garcia, V, Tarazona, N, Alemany, L, Oliva, M. ctDNA clearance after induction therapy as predictor of response to radical chemoradiotherapy in locally advanced head and neck cancer. RADIOTHERAPY AND ONCOLOGY. 2026; 216DOI:. PMID:. IF:5.300(Q1/2D).

01/06/2026 Artificial Intelligence-Assisted reflectance confocal microscopy for Real-Time intraoperative margin assessment in oral squamous cell carcinoma

Hosseinzadeh, F, Zanoni, D, França, PDD, Valero, C, Peterson, G, Ardigo, M, Ghossein, R, Dusza, SW, Pillarsetty, N, Kose, K, Wong, RJ, Ganly, I, Rajadhyaksha, M, Patel, SG. Artificial Intelligence-Assisted reflectance confocal microscopy for Real-Time intraoperative margin assessment in oral squamous cell carcinoma. ORAL ONCOLOGY. 2026; 177DOI:10.1016/j.oraloncology.2026.107939. PMID:41932031. IF:3.900(Q1/2D).

01/03/2025 Lower lip reconstruction with the Karapandzic flap or the Colmenero flap: Description of results

Sumarroca, A, Vega, C, López, S, Leidinger, A, Pedemonte, G, León, X, Costa-González, JM. Lower lip reconstruction with the Karapandzic flap or the Colmenero flap: Description of results. Acta Otorrinolaringologica Espanola. 2025; 76(2)DOI:10.1016/j.otorri.2024.10.001. PMID:39923991. IF:(Q/D).

01/03/2026 Cochlear implant failures and complications: What should radiologists look for?

Moreno, EG, Pizarro, MPV, Dotu, CO, Martínez, AL, Escalante, JEM, Beltran, JD. Cochlear implant failures and complications: What should radiologists look for?. Radiologia. 2026; 68(2)DOI:10.1016/j.rx.2025.501685. PMID:. IF:(Q/D).

01/04/2026 Final clinical data of a phase 1 dose-escalation study of WVT078, a BCMA×CD3 bispecific antibody, alone and in combination with ?-secretase inhibitor WHG626 in patients with relapsed and/or refractory multiple myeloma

Schjesvold, F, Spencer, A, Cohen, YC, Ocio, EM, Lopez-Pardo, J, Cafro, AM, Callander, NS, Kaufman, JL, Mohan, M, Wermke, M, Doki, N, Kan, RBC, Milanez-Almeida, P, Stein, A, Trabucco, G, Ye, S, Kulec, K, Sechaud, R, Banerjee, S, Zhong, HQ, Lai, CT, Rauch, PJ, Raab, MS. Final clinical data of a phase 1 dose-escalation study of WVT078, a BCMA×CD3 bispecific antibody, alone and in combination with ?-secretase inhibitor WHG626 in patients with relapsed and/or refractory multiple myeloma. CANCER. 2026; 132(7)DOI:10.1002/cncr.70341. PMID:41880322. IF:5.100(Q1/3D).

01/05/2026 Incidence and outcome of hemorrhagic cystitis after allogeneic hematopoietic cell transplantation: a survey of the infectious diseases working party of EBMT

Cesaro, S, Garonzi, C, Tridello, G, Verheggen, I, Liu, DH, Flynn, C, Alahmari, A, Kaynar, L, Rabitsch, W, Uygun, V, Chorao, P, Hu, J, Esquirol, A, Piñana, JL, Aljurf, M, Wagner-Drouet, E, Lang, PT, Martin-Sanchez, G, Ratip, S, Facchini, L, Nasilowska-Adamska, B, Styczynski, J, Ram, R, Metafuni, E, Tanase, A, Kalwak, K, Serio, B, Hashem, H, Castagna, L, Vicent, MG, Karakukcu, M, Halahleh, K, Baltadakis, I, Benedetti, E, Mikulska, M, de la Camara, R, Averbuch, D. Incidence and outcome of hemorrhagic cystitis after allogeneic hematopoietic cell transplantation: a survey of the infectious diseases working party of EBMT. BONE MARROW TRANSPLANTATION. 2026; 61(5)DOI:10.1038/s41409-026-02832-1. PMID:41888297. IF:5.200(Q1/1D).

01/04/2026 Evolving Patterns of EBV-Associated PTLD After Allogeneic Stem Cell Transplantation: Frequency, Characteristics and Outcomes in a Multicenter GETH-TC Study

García-Cadenas, I, Guerreiro, M, Yañez, L, Chorao, P, Martin, F, Suárez-Lledó, M, Pérez, A, Tomás, LG, López, J, Marsal, J, Romero, N, Huguet, M, Zabalza, A, González-Vicent, M, Vázquez, L, Silva, P, Gil, D, Micó-Cerdà, M, Sánchez, P, Filaferro, S, Balsalobre, P, Jiménez-Ubieto, A, Martino, R, Piñana, JL. Evolving Patterns of EBV-Associated PTLD After Allogeneic Stem Cell Transplantation: Frequency, Characteristics and Outcomes in a Multicenter GETH-TC Study. EUROPEAN JOURNAL OF HAEMATOLOGY. 2026; 116(4)DOI:10.1111/ejh.70109. PMID:41502050. IF:2.300(Q2/5D).

01/04/2026 Length of SARS-CoV-2 shedding in HCT recipients: an Infectious Disease Working Party of EBMT study

Mikulska, M, Tridello, G, Ljungman, P, Styczynski, J, Averbuch, D, Cesaro, S, Knelange, N, Wendel, L, Piñana, JL, Popova, M, Kröger, N, Sengeloev, H, Besley, C, Labussiere-Wallet, H, Yegin, ZA, Greco, R, Baron, F, Yonal-Hindilerden, I, Xhaard, A, Metafuni, E, Verbeek, M, Byrne, J, Toprak, SK, Grassi, A, Vallisa, D, Clay, J, Bufarull, RM, Van Gorkom, G, Sevindik, OG, Wilson, K, de la Camara, R. Length of SARS-CoV-2 shedding in HCT recipients: an Infectious Disease Working Party of EBMT study. BONE MARROW TRANSPLANTATION. 2026; 61(4)DOI:10.1038/s41409-026-02819-y. PMID:41795056. IF:5.200(Q1/1D).

01/06/2026 Pomalidomide, Cyclophosphamide and Dexamethasone (PCd): Outcomes in Patients With Double- or Triple-Refractory Multiple Myeloma

Hidalgo-Soto, M, Rodríguez-Lobato, LG, Borrella, CM, Cayuela, AS, Pardo, JL, Rosiñol, L, Cibeira, MT, García-Guiñon, A, Tolosa-Ridao, C, Arostegui, IC, Sureda, A, Herranz, MJ, Montreal, EA, Pelicano, M, Alzuria, YB, Sansa, MC, Gironella, M, González, Y, De Larrea, CF. Pomalidomide, Cyclophosphamide and Dexamethasone (PCd): Outcomes in Patients With Double- or Triple-Refractory Multiple Myeloma. EUROPEAN JOURNAL OF HAEMATOLOGY. 2026; 116(6)DOI:10.1111/ejh.70126. PMID:41652820. IF:2.300(Q2/5D).

01/01/2024 Efficacy and safety of rozanolixizumab in patients with muscle-specific tyrosine kinase autoantibody-positive generalised myasthenia gravis: a subgroup analysis of the randomised, double-blind, placebo-controlled, adaptive phase III MycarinG study

Habib, AA, Sacconi, S, Antonini, G, Cortés-Vicente, E, Grosskreutz, J, Mahuwala, ZK, Mantegazza, R, Pascuzzi, RM, Utsugisawa, K, Vissing, J, Vu, T, Wiendl, H, Boehnlein, M, Greve, B, Woltering, F, Bril, V. Efficacy and safety of rozanolixizumab in patients with muscle-specific tyrosine kinase autoantibody-positive generalised myasthenia gravis: a subgroup analysis of the randomised, double-blind, placebo-controlled, adaptive phase III MycarinG study. Therapeutic Advances in Neurological Disorders. 2024; 17DOI:10.1177/17562864241273036. PMID:39297052. IF:4.100(Q1/2D).

01/05/2026 Relevance of serum neurofilament light chain determination as a biomarker in multiple sclerosis. Consensus of the Spanish Society of Neurology's Study Group on Multiple Sclerosis and Related Neuroimmune Diseases

Domínguez, JMG, Villar, LM, Arrambide, G, Blanco, Y, Calles, MC, Casanova, B, Castillo-Triviño, T, França, LCF, Eichau, S, Pérez, MAH, Landete, L, Lallana, JM, Oreja-Guevara, C, Prieto, JM, Querol, L, Caminero, AB. Relevance of serum neurofilament light chain determination as a biomarker in multiple sclerosis. Consensus of the Spanish Society of Neurology's Study Group on Multiple Sclerosis and Related Neuroimmune Diseases. NEUROLOGIA. 2026; 41(4)DOI:10.1016/j.nrl.2025.501928. PMID:. IF:3.100(Q2/4D).

04/04/2026 Brachio-cervical inflammatory myopathy: multilevel clinical, histopathological and multi-omic analyses of a syndrome variably associated with systemic sclerosis

Kleefeld, F, Gamboa, JT, Pinal-Fernandez, I, Preusse, C, Nelke, C, Goebel, HH, Mensch, A, Mossakowski, A, Miah, MU, Diaz-Manera, J, Torchia, E, Bortolani, S, Hentschel, A, Funke, A, Souvannanorath, S, Authier, FJ, Malfatti, E, Gehrig, J, Mammen, AL, Casal-Dominguez, M, De Winter, J, De Ridder, W, Ruck, T, Schneider, U, Roos, A, Gallardo, E, Tasca, G, Stenzel, W. Brachio-cervical inflammatory myopathy: multilevel clinical, histopathological and multi-omic analyses of a syndrome variably associated with systemic sclerosis. ACTA NEUROPATHOLOGICA. 2026; 151(1)DOI:10.1007/s00401-026-03006-5. PMID:41934478. IF:9.300(Q1/1D).

01/04/2026 Assessing the Value Contribution of Vyvgart® (Efgartigimod Alfa) in the Treatment of Generalized Myasthenia Gravis with Acetylcholine Receptor Antibody in Spain Through Multi-criteria Decision Analysis

Cortés-Vicente, E, Guerrero, A, Díaz, C, Martínez, E, Toja-Camba, FJ, Abad, MR, Serra, JM, Trillo, JL, Machín, CM, Gil, A. Assessing the Value Contribution of Vyvgart® (Efgartigimod Alfa) in the Treatment of Generalized Myasthenia Gravis with Acetylcholine Receptor Antibody in Spain Through Multi-criteria Decision Analysis. ADVANCES IN THERAPY. 2026; 43(4)DOI:10.1007/s12325-026-03490-x. PMID:41591648. IF:4.000(Q1/3D).